ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
ADMA Biologics announced a peer-reviewed publication in Frontiers in Cardiovascular Medicine on its optimized IVIG manufacturing process, which effectively removed procoagulant impurities while maintaining immunoglobulin quality and increasing IgG yield. Across three commercial-scale lots, impurities including Factor XIa measured at or below quantification limits, average NAPTT exceeded 250 seconds, and no thromboembolic events were reported for optimized-process IVIG products from July 1, 2025 through July 31, 2026.
Key figures
- Naptt seconds
- 250
- Lots evaluated
- 3
- Reported tee events
- 0
- Surveillance period
- July 1, 2025 through July 31, 2026
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.